<DOC>
	<DOCNO>NCT00668382</DOCNO>
	<brief_summary>This Phase I pilot study evaluate toxicity feasibility intratumoral injection ( Glycosphingolipids ) GSL alpha-GAL ( beta-galactosidase ) patient advance , refractory solid tumor fail standard therapy eligible standard treatment .</brief_summary>
	<brief_title>Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection</brief_title>
	<detailed_description>Intratumoral injection alpha gal glycolipid experimental knockout mouse model system incorporate tumor cell membrane present xeno-transplantation epitope antigen present cell particular tumor 's tumor associate antigen ( TAA ) . Thus maneuver convert individual tumor situ tumor vaccine without need isolate , purify supply TAA exogenously . The effect model system demonstrate upregulation cytotoxic T cell react particular tumor 's TAA , well resolution inject primary tumor eradication prevention metastatic disease distant sit . This current study undertaken investigate safety feasibility approach human . The major toxicity concern acute allergic complement activation reaction development autoimmunity . The primary treatment single intratumoral injection alpha gal glycolipid . The study design standard dose escalation design primary endpoint Dose limit toxicity one month injection ( grade 3 4 . Subjects follow death utilize standard clinical imaging evaluation judge overall tumor response .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Patients solid tumor fail standard therapy , candidate standard therapy . 2 . Patients must least one measurable lesion accessible suitable injection GSL alphaGAL . 3 . Patients undergo active treatment chemotherapy , radiotherapy , steroid ( either patient treat physician decide employ therapy time , already try fail ) . If treated modality , treatment complete least two week prior date injection GSL alphaGAL . 4 . Patients judge investigator able undergo safely procedure need inject tumor GSL alphaGAL . 5 . Age equal 18 year old . 6 . ECOG ( Eastern Cooperative Oncology Group ) performance less 2 . ( International Normalized Ratio ) INR le 1.5 ( Partial Thromboplastin Time ) PTT great normal limit within 1 week prior intratumoral injection ( For patient require invasive procedure intratumoral injection ) . 7 . Laboratory Criteria ( complete equal less 2 week enrollment ) Hematologic : ( White Blood Cell Count ) WBC equal 3500/millimetercubed ( Absolute Neutrophil Count ) ANC equal 1500/millimetercubed platelet count equal 100,000/ millimetercubed . Hepatic : Total bilirubin equal le 4.0 milligrams/deciliter . Renal : Creatinine equal less 2.2 milligrams/deciliter . 8 . Patients must negative HIV ( circulate antibody ) , Hepatitis B ( circulate antigen ) , Hepatitis C ( circulate antibody ) . 9 . Patients expect survival 6 week systemic antitumor treatment plan time frame . 1 . Patients pregnant ( determined positive serum HCG ( Human Chorionic Gonadotropin ) patient childbearing potential ) nursing . 2 . Patients age 18 . 3 . Patients severe infection septicemia . 4 . Patients history autoimmune disease . 5 . Patients , , active treatment chemotherapy steroid . 6 . Patients refuse HIV/hepatitis test patient sign approve consent form . 7 . Patient receive investigational drug within 14 day enrollment expect participate experimental drug study study treatment . 8 . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cancerous solid tumor</keyword>
	<keyword>Alpha-Gal Glycosphingolipids</keyword>
</DOC>